A5091865528- Rheumatoid Arthritis Research and Therapies
- Autoimmune and Inflammatory Disorders Research
- Chronic Lymphocytic Leukemia Research
- Psoriasis: Treatment and Pathogenesis
- Pancreatic and Hepatic Oncology Research
- Palliative Care and End-of-Life Issues
- Spondyloarthritis Studies and Treatments
- Sepsis Diagnosis and Treatment
- SARS-CoV-2 and COVID-19 Research
- Dermatological and COVID-19 studies
- Inflammatory Bowel Disease
- Parkinson's Disease and Spinal Disorders
- Peripheral Neuropathies and Disorders
- Immunodeficiency and Autoimmune Disorders
- Intramuscular injections and effects
- Lymphoma Diagnosis and Treatment
University Hospitals of Cleveland
2022-2024
Case Western Reserve University
2022-2024
Veterans Health Administration
2022-2024
University School
2023
American University of Beirut
2022
American University of Beirut Medical Center
2020-2021
Decisions regarding whether advanced cancer patients should be admitted to the ICU are based on a complex suite of considerations, including short- and long-term prognosis, quality life, therapeutic options treat cancer. We aimed describe demographic, clinical, survival data identify factors associated with mortality in critically ill nonelective admissions general ICUs.
The COVID-19 pandemic has been a prime health issue since December 2019. Consequently, there an urgent need to prevent severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) infection and its associated morbidity mortality. currently available vaccines are designed infection. Their efficacy safety have demonstrated in clinical trials. Yet, given the short duration of trials urgency start vaccination, adverse events reported worldwide real-life data format. Immune-mediated disease...
The aim of the Lebanese hospital-based Rheumatoid Arthritis (RA) registry, initiated in 2011, is to evaluate safety and efficacy biologic agents among patients seeking care at American University Beirut Medical Center (AUBMC). We aimed characterize demographic clinical profile RA included registry. compared our results with those issued from Middle Eastern non-Middle registries.195 Patients enrolled registry 2011 2018 were considered this study. eligible be treated biologics, but 56 remained...
Background Rituximab, a chimeric monoclonal antibody targeting the CD20 protein on surface of B cells, is used to treat several rheumatologic and oncologic diseases. The standard infusion duration rituximab four hours. Objective Evaluating safety administering accelerated 90-minute protocol at our Veterans Affairs center patients with diseases monitoring for any infusion-related reactions. This study unique as it examines rates faster than those most described (120 minutes). Methods Patients...
Objectives: Infliximab (Remicade®) was the first tumour necrosis factor-α (TNF) inhibitor to receive its initial marketing approval from US Food and Drug Administration (FDA) for treatment of Crohn's disease.Following that, infliximab became approved several immune-mediated inflammatory diseases.No evidence exists in Middle East North Africa region on experience with use over an extended period terms efficacy safety.Methods: The Rheumatology division at American University Beirut Medical...